Answers are grounded in this paper and cite their sources.
Prof Marcus Maurer opened the symposium with an introduction to chronic urticaria (CU), as well as its two subtypes (chronic spontaneous urticaria [CSU] and chronic inducible urticaria [CIndU]), and the currently available therapeutic strategies. Dr Clive Grattan spoke about the burden of disease in patients with CSU and the specific effects it has on a patient’s quality of life as well as the socioeconomic impact. Dr Donald Stull explained the importance of measuring the impact of disease using patient reported outcomes. Prof Ana Giménez-Arnau concluded the symposium by presenting the latest data on omalizumab for refractory CSU while touching on the recommendations in the latest urticaria guidelines. Interactive keypads were available throughout the symposium which allowed delegates to vote on different questions about their experience in treating patients with urticaria, posed by the speakers.
No takes yet. Share an insight, caveat, or question.
Saroshi Amirthalingam (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: